What Faron Pharmaceuticals does

Faron Pharmaceuticals Ltd is a Finnish clinical-stage biopharmaceutical company developing macrophage-targeting immunotherapy for hematological malignancies. The company's lead asset, bexmarilimab, is a first-in-class humanized monoclonal antibody directed against the Clever-1 receptor expressed on tumor-associated macrophages. By blocking Clever-1, bexmarilimab reprograms immunosuppressive M2 macrophages into immunostimulatory M1 macrophages, upregulating interferon production, increasing antigen presentation, and sensitizing cancer cells to standard-of-care hypomethylating agents (azacitidine). The lead indication is higher-risk myelodysplastic syndrome (HR MDS), with secondary investigation in acute myeloid leukemia (AML) and combination approaches in solid tumors (NSCLC, melanoma) via the BLAZE trial with the Institute for Cancer Research. Faron is also developing earlier-stage candidates Traumakine (intravenous interferon beta for ischemia-reperfusion injury) and Haematokine (blood cell expansion).

The company operates a sales-led, partnership-oriented commercial model. As a pre-revenue clinical-stage entity, Faron has no marketed products and reported an operating loss of EUR 19.0 million for 2025 with negative net assets of EUR 18.5 million. Future revenue is expected to come from direct sales of bexmarilimab through hospital/specialty pharmacy channels targeting hematologists and oncologists, augmented by potential global licensing or co-promotion arrangements with larger pharmaceutical partners that the company is actively pursuing. Pricing has not been disclosed, but orphan-drug economics are expected. The company is dual-listed on London's AIM (FARN) and Nasdaq First North Growth Market Finland (FARON), with headquarters in Turku, Finland, and subsidiaries in the United States (Faron USA LLC, Delaware) and Switzerland (Faron Europe GmbH). Recent financing has extended the cash runway to November 2027.

Name

Faron Pharmaceuticals

Legal name

Faron Pharmaceuticals Ltd

Website

https://faron.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Faron Pharmaceuticals is a Finnish clinical-stage biopharmaceutical company developing bexmarilimab, a first-in-class anti-Clever-1 monoclonal antibody that reprograms macrophages to treat higher-risk myelodysplastic syndrome (HR MDS) and other hematological malignancies.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy Pharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Cancer immunotherapy drugs
• Monoclonal antibody therapy
• Hematological malignancy treatment
• Myelodysplastic syndrome drug
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Turku

HQ country

Finland

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Pharmaceutical product sales: Pre-revenue clinical stage company. Upon regulatory approval, expects to generate revenue from sales of bexmarilimab for treatment of higher-risk myelodysplastic syndrome (HR MDS) and potentially other hematological malignancies. Revenue model will be traditional specialty pharmaceutical with hospital/specialty pharmacy distribution.
2. Potential licensing/partnership revenue: Company is in active commercial discussions with potential pharmaceutical partners for global commercialization rights or co-development arrangements for bexmarilimab. May generate upfront payments, milestone payments, and royalty revenue through licensing deals.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Faron Pharmaceuticals develops investigational immunotherapies for cancer, with lead asset bexmarilimab, a first-in-class anti-Clever-1 antibody currently in Phase I/II clinical trials for higher-risk myelodysplastic syndrome (HR MDS) and acute myeloid leukemia (AML). The company also has earlier-stage candidates Traumakine (interferon beta for trauma-related multi-organ damage) and Haematokine (blood cell expansion). All products are investigational with no approved products on the market.

Product overview

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. The company's lead asset is bexmarilimab, a first-in-class anti-Clever-1 antibody currently in Phase I/II clinical trials for hematological malignancies including high-risk myelodysplastic syndrome (HR-MDS) and acute myeloid leukemia (AML). The company is also developing earlier-stage candidates Traumakine and Haematokine for trauma-related applications. All products are investigational and have not received regulatory approval.

Differentiator

Problem solved

Functional benefit

Products and services

• Bexmarilimab First-in-class anti-Clever-1 humanized monoclonal antibody immunotherapy candidate investigated in Phase I/II clinical trials for hematological cancers (higher-risk myelodysplastic syndrome and acute myeloid leukemia), in combination with standard-of-care azacitidine. It reprograms immunosuppressive macrophages to immunostimulatory M1 state to attack tumors.
• Traumakine An investigational immune modulation drug candidate based on intravenous interferon beta, being developed for multi-organ damage, inflammation, and blood abnormalities, with research focus on battlefield wounds and tissue preservation under a US Department of Defense grant consortium.
• Haematokine Investigational drug candidate in development for blood cell expansion and addressing blood abnormalities related to trauma and injury.

Quantifiable outcome

• 85% ORR (17/20 evaluable) and 45% CR rate in treatment-naïve HR-MDS patients
• +5 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Four partnerships are on record, tiered major and minor.

• City of HopemajorStrategic or Co-development Partner · 1 March 2026City of Hope, a leading US cancer research and treatment center, is collaborating with Faron to develop a Phase II investigator-initiated trial evaluating bexmarilimab in relapsed/refractory MDS. Trial combines bexmarilimab with oral hypomethylating agent decitabine/cedazuridine. First patient enrollment expected H2 2026 pending regulatory approvals.
• Nordic AML GroupmajorStrategic or Co-development Partner · 1 February 2026Nordic AML Group leading Phase II BEAM-X Investigator-Initiated Trial evaluating bexmarilimab in combination with azacitidine for MRD-positive AML patients following allogeneic stem cell transplantation. Trial will enroll 24 patients with primary endpoint of MRD negativity at six months. First patient expected Q3 2026.
• The Institute for Cancer ResearchmajorStrategic or Co-development Partner · 1 December 2025Strategic collaboration with The Institute for Cancer Research in London to launch the BLAZE trial. Phase I/II study investigating bexmarilimab in overcoming resistance to anti-PD-1 immunotherapy in cancer patients. Novel approach primes patients with bexmarilimab before combination with zimberelimab for metastatic NSCLC and melanoma.
• BMIOrganbankminorStrategic or Co-development Partner · 1 August 2024Collaboration as part of US Department of Defense grant consortium to develop tissue preservation strategies for transplants. BMIOrganbank leading academic center collaboration in Pennsylvania and North Carolina. Research focuses on using intravenous interferon beta to prevent ischemia-reperfusion injury in battlefield trauma cases.

Scale indicators7 records

Expansion highlights6 records

Emerging players

• Disc Medicine: Clinical-stage biopharma developing therapeutics for hematologic diseases including MDS-related cytopenias — a comparable small-cap, late-clinical hematology player with similar orphan-drug regulatory positioning.
• Notable Labs: Clinical-stage precision medicine company focused on functional drug profiling in blood cancers including MDS and AML — comparable small-cap, indication-aligned, biomarker-driven development approach.
• Gilead Sciences (Magrolimab program): Gilead's magrolimab is a macrophage-targeting immunotherapy (anti-CD47) for HR MDS and AML, making it the most directly relevant technology competitor to bexmarilimab's Clever-1 macrophage-reprogramming approach.

Broad incumbents

• AbbVie: Markets venetoclax (Bcl-2 inhibitor) in combination with azacitidine for AML — the dominant standard-of-care against which bexmarilimab + azacitidine will be benchmarked in AML expansion.
• Pfizer (Trillium Therapeutics): Acquired Trillium Therapeutics to access SIRPα/CD47 macrophage-checkpoint programs — directly relevant to bexmarilimab's macrophage-reprogramming mechanism and signals big-pharma appetite for myeloid-cell immunotherapy assets.
• Bristol-Myers Squibb: Markets Reblozyl (luspatercept) for MDS-related anemia and has deep hematology/oncology commercial infrastructure — a major incumbent in the HR MDS treatment landscape where bexmarilimab would compete or partner.

Direct peers

• Sobi (CTI BioPharma): Acquired CTI BioPharma and now markets Vonjo (pacritinib) for myelofibrosis, representing another late-stage hematology asset that reached commercialization via acquisition — a relevant exit-comparable.
• Syros Pharmaceuticals: Clinical-stage biopharma focused on hematologic malignancies and defined patient populations, with a similar small-cap, late-clinical positioning and comparable regulatory pathway strategy.
• MorphoSys (Novartis): Developed pelabresib for myelofibrosis and other hematologic malignancies — recently acquired by Novartis — and represents a comparable European-headquartered clinical-stage hematology company that ultimately secured a big-pharma exit.
• Geron Corporation: Clinical-stage biopharma developing imetelstat for lower-risk MDS — the closest direct comparator to Faron given overlapping indication (MDS), similar regulatory approach (orphan designation), and comparable clinical-stage commercial positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/FaronPharm
• LinkedInlinkedin.com/company/faron

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds14 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Faron Pharmaceuticals